Beximco Pharma continues its endeavor to offer new molecules first time in Bangladesh by launching Cesonide ^® (Ciclesonide 80 & 160 mcg inhaler) for persistent asthma treatment in adults. Ciclesonide is a new once daily inhaled corticosteroid that produces high local anti-inflammatory activity in asthmatic airways. Cesonide ^® offers advantages in terms of local & systemic side effects over other inhaled corticosteroids and ensures safety to the patients.

• Unique properties make ciclesonide different from other ICSs
  
• On-site activation
  
• Prolonged lung residence time
  
• Very high plasma protein binding and systemic clearance
  
• Efficacy comparable to fluticasone and budesonide
  
• Convenient once-daily dosing

CONSUMER MEDICINE INFORMATION